Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More
CIPLA | PIRAMAL ENTERPRISES | CIPLA/ PIRAMAL ENTERPRISES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 35.8 | -38.4 | - | View Chart |
P/BV | x | 4.2 | 1.3 | 321.3% | View Chart |
Dividend Yield | % | 0.5 | 1.8 | 27.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
PIRAMAL ENTERPRISES Mar-19 |
CIPLA/ PIRAMAL ENTERPRISES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 3,303 | 17.7% | |
Low | Rs | 357 | 1,797 | 19.9% | |
Sales per share (Unadj.) | Rs | 207.0 | 716.5 | 28.9% | |
Earnings per share (Unadj.) | Rs | 18.6 | 79.7 | 23.3% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 107.9 | 30.7% | |
Dividends per share (Unadj.) | Rs | 4.00 | 28.00 | 14.3% | |
Dividend yield (eoy) | % | 0.8 | 1.1 | 77.3% | |
Book value per share (Unadj.) | Rs | 195.5 | 1,477.5 | 13.2% | |
Shares outstanding (eoy) | m | 806.35 | 184.45 | 437.2% | |
Bonus/Rights/Conversions | ESOS | IS | - | ||
Price / Sales ratio | x | 2.3 | 3.6 | 63.9% | |
Avg P/E ratio | x | 25.3 | 32.0 | 79.2% | |
P/CF ratio (eoy) | x | 14.2 | 23.6 | 60.1% | |
Price / Book Value ratio | x | 2.4 | 1.7 | 139.7% | |
Dividend payout | % | 21.5 | 35.1 | 61.2% | |
Avg Mkt Cap | Rs m | 379,912 | 470,292 | 80.8% | |
No. of employees | `000 | 25.8 | 7.8 | 330.5% | |
Total wages/salary | Rs m | 30,270 | 22,504 | 134.5% | |
Avg. sales/employee | Rs Th | 6,459.6 | 16,899.4 | 38.2% | |
Avg. wages/employee | Rs Th | 1,171.2 | 2,877.7 | 40.7% | |
Avg. net profit/employee | Rs Th | 580.2 | 1,879.9 | 30.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 132,153 | 126.3% | |
Other income | Rs m | 3,442 | 3,128 | 110.0% | |
Total revenues | Rs m | 170,391 | 135,281 | 126.0% | |
Gross profit | Rs m | 32,060 | 66,290 | 48.4% | |
Depreciation | Rs m | 11,747 | 5,202 | 225.8% | |
Interest | Rs m | 1,974 | 44,097 | 4.5% | |
Profit before tax | Rs m | 21,782 | 20,119 | 108.3% | |
Minority Interest | Rs m | -475 | 3,194 | -14.9% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6,312 | 8,611 | 73.3% | |
Profit after tax | Rs m | 14,995 | 14,701 | 102.0% | |
Gross profit margin | % | 19.2 | 50.2 | 38.3% | |
Effective tax rate | % | 29.0 | 42.8 | 67.7% | |
Net profit margin | % | 9.0 | 11.1 | 80.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 122,742 | 95.4% | |
Current liabilities | Rs m | 43,931 | 310,810 | 14.1% | |
Net working cap to sales | % | 43.8 | -142.3 | -30.8% | |
Current ratio | x | 2.7 | 0.4 | 674.6% | |
Inventory Days | Days | 96 | 23 | 414.9% | |
Debtors Days | Days | 85 | 39 | 219.0% | |
Net fixed assets | Rs m | 107,424 | 116,904 | 91.9% | |
Share capital | Rs m | 1,613 | 369 | 437.1% | |
"Free" reserves | Rs m | 156,018 | 272,161 | 57.3% | |
Net worth | Rs m | 157,630 | 272,530 | 57.8% | |
Long term debt | Rs m | 23,693 | 270,196 | 8.8% | |
Total assets | Rs m | 236,626 | 856,261 | 27.6% | |
Interest coverage | x | 12.0 | 1.5 | 826.6% | |
Debt to equity ratio | x | 0.2 | 1.0 | 15.2% | |
Sales to assets ratio | x | 0.7 | 0.2 | 457.1% | |
Return on assets | % | 7.2 | 6.9 | 104.4% | |
Return on equity | % | 9.5 | 5.4 | 176.3% | |
Return on capital | % | 12.8 | 12.4 | 103.4% | |
Exports to sales | % | 33.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 55,175 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 56,036 | 15,200 | 368.6% | |
Fx outflow | Rs m | 6,764 | 4,889 | 138.4% | |
Net fx | Rs m | 49,272 | 10,312 | 477.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | -115,975 | -26.5% | |
From Investments | Rs m | 1,040 | -8,265 | -12.6% | |
From Financial Activity | Rs m | -29,488 | 107,525 | -27.4% | |
Net Cashflow | Rs m | 2,340 | -16,650 | -14.1% |
Indian Promoters | % | 16.0 | 52.9 | 30.2% | |
Foreign collaborators | % | 20.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 12.2 | 4.0 | 305.0% | |
FIIs | % | 23.7 | 26.6 | 89.1% | |
ADR/GDR | % | 1.1 | 0.0 | - | |
Free float | % | 26.2 | 16.5 | 158.8% | |
Shareholders | 161,166 | 93,274 | 172.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: PFIZER GSK PHARMA PANACEA BIOTECH ORCHID PHARMA ABBOTT INDIA
Compare CIPLA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
After opening the day on a strong note, Indian share markets witnessed a sharp sell-off during closing hours today and ended lower.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More